Viserve Enterprise PCL logo

Viserve Enterprise PCL (VS.R)

Market Closed
11 Aug, 23:30
SET SET
฿
0. 26
-0.51
-66.0477%
฿
- Market Cap
- P/E Ratio
- Div Yield
20,400 Volume
0 Eps
฿ 0.77
Previous Close
Add Transaction
Day Range
0.25 0.26
Year Range
0.18 0.77
Want to track VS.R and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

VS.R closed today lower at ฿0.26, a decrease of -66.0477% from yesterday's close, completing a monthly decrease of -66.0477% or -฿0.51. Over the past 12 months, VS.R stock lost -7.1429%.
VS.R is not paying dividends to its shareholders.
The last earnings report, released on Feb 20, 2025, missed the consensus estimates by -0.0558%. On average, the company has fell short of earnings expectations by -0.0558%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on SET (THB).

VS.R Chart

Viserve Enterprise PCL (VS.R) FAQ

What is the stock price today?

The current price is ฿0.26.

On which exchange is it traded?

Viserve Enterprise PCL is listed on SET.

What is its stock symbol?

The ticker symbol is VS.R.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Viserve Enterprise PCL ever had a stock split?

No, there has never been a stock split.

Viserve Enterprise PCL Profile

Biotechnology Industry
Healthcare Sector
Oludare Odumosu CEO
SET Exchange
TH8980010004 ISIN
AU Country
8 Employees
- Last Dividend
- Last Split
28 Jul 2003 IPO Date

Overview

Zelira Therapeutics Limited is a bio-pharmaceutical company that specializes in the research, development, and commercialization of cannabinoid-based medicines. The company has a focus on treating a wide range of medical conditions through its research and development efforts in Australia and the United States. The company was initially known as Zelda Therapeutics Limited but underwent a name change to Zelira Therapeutics Limited in December 2019. Since its inception in 2003, Zelira Therapeutics has established itself as a leader in cannabinoid-based therapies, boasting a diverse portfolio of products across various therapeutic areas. The company's headquarters are located in Perth, Australia, solidifying its presence both domestically and internationally.

Products and Services

  • HOPE Brand Formulations

    Zelira Therapeutics offers a range of cannabinoid-based formulations under the HOPE brand. These formulations are available in Australia, Washington, Pennsylvania, and Louisiana, designed to meet the needs of patients suffering from various medical conditions. The HOPE brand represents the company's commitment to providing innovative and effective treatments.

  • Zenivol

    Zenivol is a cannabinoid-based medicine developed by Zelira Therapeutics specifically for the treatment of chronic insomnia. This product signifies the company's effort to address a significant and often difficult-to-treat condition, showcasing their expertise in leveraging cannabinoids for therapeutic purposes.

  • Over the Counter Products

    Zelira Therapeutics also offers over-the-counter products, further expanding its reach beyond prescription medications. These include:

    • SprinJene - An oral care product that combines the benefits of cannabinoids with traditional oral hygiene practices.
    • RAF FIVE - A dermatology product designed to leverage the therapeutic properties of cannabinoids for skin health.
    • Zyraydi - This product utilizes enhanced distillate capture and dissolution matrix technology, offering a novel approach to cannabinoid-based therapies.

Contact Information

Address: 101 St George's Terrace
Phone: 61 8 6558 0886